General Biologicals Corporation (TPEX:4117)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.20
-0.10 (-0.97%)
Aug 19, 2026, 1:20 PM CST

General Biologicals Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
260.23215.74251.93264.83370.46551.66
Revenue Growth
20.62%-14.36%-4.87%-28.51%-32.85%15.93%
Gross Profit
92.1459.627.5462.71171.85281.94
Operating Income
-139.67-197.05-215.78-169.94-40.8743.79
Net Income
518.98465.84-220.82-198.83-53.1944.14
Earnings Per Share
7.677.44-3.69-3.32-0.890.74
EPS Growth
3.06%-----37.38%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Medical Technology
43.5143.5170.24158.27129.73182.85
Adjustment and Elimination
-15.16-15.16-8.12-60.29-44.57-27.44
Diagnostic Reagents
102.9102.9155.46132.69258.54396.24
Protein New Drug
54.6854.6834.3434.1426.76-
Lease Management
29.8129.81----
Total
215.74215.74251.93264.83370.46551.66

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
604.26634.75251.65217.12351.08368.77
Total Debt
2,4162,4962,310548.46468.82449.44
Net Cash (Debt)
-1,812-1,862-2,058-331.34-117.74-80.66
Net Cash Growth
------
Net Cash Per Share
-26.78-29.74-34.40-5.54-1.97-1.35

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-77.27-127.26-189.68225.68225.0138.97
Capital Expenditures
-9.74-180.02-1,545-424.02-248.42-14.73
Free Cash Flow
-87.01-307.28-1,735-198.33-23.4224.24
Free Cash Flow Growth
-----3.23%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
35.41%27.63%2.99%23.68%46.39%51.11%
Operating Margin
-53.67%-91.34%-85.65%-64.17%-11.03%7.94%
Pretax Margin
216.12%234.31%-88.17%-70.88%-12.45%7.00%
Profit Margin
199.43%215.93%-87.65%-75.08%-14.36%8.00%
FCF Margin
-33.44%-142.43%-688.57%-74.89%-6.32%4.40%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
1.401.68---47.16
P/FCF Ratio
-----85.87
PS Ratio
2.913.625.066.104.343.77